• 1
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
  • 2
    Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474: S18-S19.
  • 3
    Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197-207.
  • 4
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
  • 5
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
  • 6
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
  • 7
    Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. HEPATOLOGY 2004; 39: 476-483.
  • 8
    Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006; 42: 82-91.
  • 9
    Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, et al. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 1403-1411.
  • 10
    Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, Howell CD. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2: 463-468.
  • 11
    Harzke AJ, Baillargeon JG, Kelley MF, Diamond PM, Goodman KJ, Paar DP. HCV-related mortality among male prison inmates in Texas, 1994-2003. Ann Epidemiol 2009; 19: 582-589.
  • 12
    Rosen DL, Schoenbach VJ, Wohl DA. All-cause and cause-specific mortality among men released from state prison, 1980-2005. Am J Public Health 2008; 98: 2278-2284.
  • 13
    Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. HEPATOLOGY 2008; 47: 1128-1135.
  • 14
    Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Racial difference in mortality among U.S. veterans with HCV/HIV coinfection. Am J Gastroenterol 2006; 101: 760-767.
  • 15
    Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9: 117-125.
  • 16
    Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 2010; 48: S96-S105.
  • 17
    Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. HEPATOLOGY 2003; 37: 590-599.
  • 18
    Bonacini M, Groshen MD, Yu MC, Govindarajan S, Lindsay KL. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001; 96: 2438-2441.
  • 19
    Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, et al. Histological versus clinical cirrhosis in chronic hepatitis C: does race/ethnicity really matter? Dig Dis Sci 2012; 57: 771-776.
  • 20
    Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A. More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006; 101: 1817-1823.
    Direct Link:
  • 21
    Barreiro P, Pineda JA, Rallon N, Naggie S, Martin-Carbonero L, Neukam K, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis 2011; 203: 1629-1636.
  • 22
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 23
    Lutz P, Wasmuth JC, Nischalke HD, Vidovic N, Grunhage F, Lammert F, et al. Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Eur J Med Res 2011; 16: 335-341.
  • 24
    Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. HEPATOLOGY 2011; 54: 1127-1134.
  • 25
    Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011; 31: 891-899.